title: EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?
authors: Denise L
authors: DL
authors: Faustman
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D017252:CD3 Complex / Q000276:immunology*; D017326:Clinical Trials, Phase III as Topic; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy*; D054796:Drug Dosage Calculations; D020031:Epstein-Barr Virus Infections / Q000276:immunology*; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D051379:Mice; D016688:Mice, Inbred NOD; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D014775:Virus Activation
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D014409:Tumor Necrosis Factor-alpha
references: Mol Cell Biol. 1999 Dec;19(12):8646-59
references: 10567588
references: Nat Rev Drug Discov. 2010 Jun;9(6):482-93
references: 20489699
references: PLoS One. 2012;7(8):e41756
references: 22905105
references: Nature. 2012 Jan 25;481(7382):480-3
references: 22281596
references: Ann Rheum Dis. 2006 Aug;65(8):1021-7
references: 16414974
references: BMJ. 1989 Nov 18;299(6710):1259-60
references: 2513902
references: Clin Immunol. 2010 Feb;134(2):121-9
references: 19837003
references: Eur J Immunol. 2010 Oct;40(10):2891-901
references: 21038470
references: Adv Physiol Educ. 2006 Dec;30(4):152-8
references: 17108242
references: Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13644-9
references: 18755894
references: Nat Med. 2000 Oct;6(10):1065-6
references: 11017113
references: J Immunol. 1997 Sep 15;159(6):3068-80
references: 9300732
references: Ann N Y Acad Sci. 1998 Apr 15;842:138-55
references: 9599304
references: N Engl J Med. 2002 May 30;346(22):1692-8
references: 12037148
references: N Engl J Med. 2005 Jun 23;352(25):2598-608
references: 15972866
references: Lancet. 2011 Aug 6;378(9790):487-97
references: 21719095
references: PLoS Pathog. 2006 Feb;2(2):e4
references: 16518473